2023
DOI: 10.17712/nsj.2023.2.20220133
|View full text |Cite
|
Sign up to set email alerts
|

The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology

Abstract: Alzheimer Disease (AD) constitutes a major global healthcare problem. Standard AD pharmacotherapies offer only modest transient cognitive and behavioral benefits. Aducanumab, an amyloid monoclonal antibody, was the first disease modifying agent to be approved for AD treatment. However, concerns about its efficacy and side effects led regulatory institutions around the world to restrict its use. Lecanemab was the second amyloid antibody to receive accelerated approval for use in early AD. This review and consen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 33 publications
0
1
0
Order By: Relevance
“…Measuring the burden of BPSD is important in Saudi AD patients to ameliorate their impact on patients and caregivers. There are numerous immunotherapies being developed for the treatment of AD 35 . BPSDs may be affected by these new treatments and these symptoms must therefore be carefully assessed, followed up and managed.…”
Section: Discussionmentioning
confidence: 99%
“…Measuring the burden of BPSD is important in Saudi AD patients to ameliorate their impact on patients and caregivers. There are numerous immunotherapies being developed for the treatment of AD 35 . BPSDs may be affected by these new treatments and these symptoms must therefore be carefully assessed, followed up and managed.…”
Section: Discussionmentioning
confidence: 99%
“…As AD is managed by multiple specialties, integration of these subdomains is essential for the well-being of the patient [ 29 ]. Lack of knowledge on caregiving may to some extent delay the management and interventions provided to patients diagnosed with AD and lead to adverse effects on their quality of life [ 30 ].…”
Section: Discussionmentioning
confidence: 99%